Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 6. Annual reported cases of notifiable diseases and rates per 100,000, by race*,†, excluding U.S. Territories - - United States, 2018
Disease American Indian or
Alaska Native		 Asian or Pacific
Islander		 Black White Other Race Race not stated Total
No. Rate No. Rate No. Rate No. Rate No. No. No.
Anthrax S S S S S S S S S S 1
Arboviral diseases
Chikungunya virus disease — — 33 0.15 6 0.01 31 0.01 7 40 117
Eastern equine encephalitis virus disease
Neuroinvasive S S S S S S S S S S 6
Non-neuroinvasive — — — — — — — — — — —
Jamestown Canyon virus disease
Neuroinvasive — — — — 1 0.00 17 0.01 4 3 25
Non-neuroinvasive S S S S S S S S S S 16
La Crosse virus disease
Neuroinvasive 3 0.06 — — 1 0.00 72 0.03 1 6 83
Non-neuroinvasive S S S S S S S S S S 3
Powassan virus disease
Neuroinvasive S S S S S S S S S S 21
Non-neuroinvasive — — — — — — — — — — —
St. Louis encephalitis virus disease
Neuroinvasive S S S S S S S S S S 5
Non-neuroinvasive S S S S S S S S S S 3
West Nile virus disease
Neuroinvasive 18 0.38 21 0.10 125 0.27 1,132 0.44 76 285 1,657
Non-neuroinvasive 21 0.44 9 0.04 29 0.06 661 0.26 33 236 989
Western equine encephalitis virus disease
Neuroinvasive — — — — — — — — — — —
Non-neuroinvasive — — — — — — — — — — —
Babesiosis
Total 6 0.18 57 0.31 38 0.10 1,294 0.61 97 668 2,160
Confirmed 5 0.15 49 0.27 35 0.10 1,123 0.53 92 557 1,861
Probable 1 0.03 8 0.04 3 0.01 171 0.08 5 111 299
Botulism
Total 4 0.08 8 0.04 7 0.02 153 0.06 17 36 225
Foodborne S S S S S S S S S S 17
Infant 2 2.68 6 2.51 3 0.45 108 3.76 5 33 157
Other (wound & unspecified) — — — — 3 0.01 35 0.01 10 3 51
Brucellosis 3 0.06 6 0.03 12 0.03 76 0.03 20 21 138
Campylobacteriosis 523 11.04 1,988 9.20 3,631 7.85 43,146 16.95 6,820 14,092 70,200
Chancroid S S S S S S S S S S 3
Chlamydia trachomatis infection 20,089 423.88 29,331 135.78 487,967 1,054.77 543,911 213.66 126,988 550,382 1,758,668
Cholera S S S S S S S S S S 14
Coccidioidomycosis § 192 7.78 478 4.68 575 3.98 4,828 4.48 3,732 5,806 15,611
Cryptosporidiosis
Total 68 1.43 192 0.89 941 2.03 8,837 3.47 665 1,830 12,533
Confirmed 48 1.01 134 0.62 704 1.52 6,158 2.42 505 1,431 8,980
Probable 20 0.42 58 0.27 237 0.51 2,679 1.05 160 399 3,553
Cyclosporiasis 13 0.32 67 0.33 136 0.33 2,468 1.09 300 535 3,519
Dengue virus infections 
Dengue 1 0.02 70 0.32 18 0.04 175 0.07 37 123 424
Dengue-like illness — — 8 0.04 3 0.01 19 0.01 2 9 41
Severe dengue S S S S S S S S S S 9
Diphtheria S S S S S S S S S S 1
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 21 0.50 28 0.14 15 0.03 2,684 1.09 145 1,115 4,008
Ehrlichia chaffeensis infection 6 0.14 9 0.04 52 0.11 1,161 0.47 54 517 1,799
Ehrlichia ewingii infection — — — — 1 0.00 24 0.01 2 6 33
Undetermined ehrlichiosis/anaplasmosis 1 0.02 2 0.01 2 0.00 206 0.09 26 46 283
Giardiasis 94 2.57 374 2.03 979 2.80 7,863 3.94 1,916 4,322 15,548
Gonorrhea 8,427 177.81 7,851 36.35 224,280 484.80 178,560 70.14 35,842 128,445 583,405
Haemophilus influenzae, invasive disease
All ages, all serotypes 91 1.92 90 0.42 731 1.58 3,511 1.38 176 974 5,573
Age <5 years
Serotype b 3 0.79 — — 3 0.09 25 0.17 1 6 38
Non-b serotype 22 5.79 2 0.16 44 1.30 89 0.60 6 28 191
Nontypeable 9 2.37 8 0.62 33 0.97 131 0.89 11 30 222
Unknown serotype 5 1.32 11 0.86 23 0.68 84 0.57 21 31 175
Hansen's disease 1 0.03 13 0.07 4 0.01 40 0.02 5 27 90
Hantavirus infection, non-hantavirus pulmonary syndrome S S S S S S S S S S 2
Hantavirus pulmonary syndrome S S S S S S S S S S 18
Hemolytic uremic syndrome post-diarrheal 4 0.09 11 0.05 11 0.02 282 0.11 35 33 376
Hepatitis **
A, acute 15 0.32 108 0.50 506 1.09 8,793 3.45 794 2,258 12,474
B, acute 26 0.55 56 0.26 409 0.89 2,201 0.87 142 488 3,322
B, perinatal infection S S S S S S S S S S 23
C, acute 94 2.27 32 0.15 277 0.63 3,428 1.42 265 672 4,768
Confirmed 84 2.03 28 0.13 241 0.55 2,535 1.05 220 513 3,621
Probable 10 0.24 4 0.02 36 0.08 893 0.37 45 159 1,147
C, perinatal infection 1 0.02 1 0.01 3 0.01 102 0.04 16 91 214
Human immunodeficiency virus diagnoses 165 3.48 776 3.59 14,354 31.03 8,822 3.47 8,882 — 32,999
Influenza-associated pediatric mortality 4 0.29 6 0.13 27 0.22 102 0.19 3 17 159
Invasive pneumococcal disease ††
All ages 311 10.53 302 2.42 3,035 7.98 11,900 6.25 694 3,615 19,857
Confirmed 306 10.36 299 2.39 3,001 7.89 11,759 6.18 678 3,576 19,619
Probable 5 0.17 3 0.02 34 0.09 141 0.07 16 39 238
Age <5 years 21 0.60 37 0.28 236 0.58 571 0.28 39 212 1,116
Confirmed 20 6.99 37 4.44 230 7.73 548 4.66 37 206 1,078
Probable 1 0.35 — — 6 0.20 23 0.20 2 6 38
Legionellosis 49 1.03 117 0.54 2,251 4.87 6,037 2.37 495 984 9,933
Leptospirosis — — 6 0.03 — — 45 0.02 18 22 91
Listeriosis 3 0.06 52 0.24 94 0.20 553 0.22 55 107 864
Lyme disease
Total 80 1.69 222 1.07 248 0.54 17,507 6.89 761 14,848 33,666
Confirmed 53 1.12 147 0.71 161 0.35 12,063 4.75 578 10,556 23,558
Probable 27 0.57 75 0.36 87 0.19 5,444 2.14 183 4,292 10,108
Malaria 2 0.04 79 0.37 1,156 2.50 185 0.07 95 231 1,748
Measles
Total — — 15 0.07 5 0.01 230 0.09 7 118 375
Indigenous — — 1 0.00 1 0.00 189 0.07 4 101 296
Imported — — 14 0.06 4 0.01 41 0.02 3 17 79
Meningococcal disease
All serogroups 3 0.06 12 0.06 40 0.09 214 0.08 16 42 327
Serogroups ACWY 1 0.02 4 0.02 14 0.03 66 0.03 4 11 100
Serogroup B 2 0.04 6 0.03 4 0.01 58 0.02 3 8 81
Other serogroups — — — — 7 0.02 14 0.01 — 2 23
Unknown serogroup — — 2 0.01 15 0.03 76 0.03 9 21 123
Mumps 36 0.76 388 1.80 215 0.46 1,077 0.42 94 705 2,515
Novel Influenza A virus infections S S S S S S S S S S 14
Paratyphoid fever §§ 4 0.08 44 0.20 4 0.01 42 0.02 16 23 133
Pertussis 288 6.08 325 1.50 650 1.41 10,778 4.23 608 2,960 15,609
Plague S S S S S S S S S S 1
Poliomyelitis, paralytic — — — — — — — — — — —
Poliovirus infection, nonparalytic — — — — — — — — — — —
Psittacosis S S S S S S S S S S 22
Q fever
Total 3 0.06 8 0.04 5 0.01 140 0.06 31 28 215
Acute 3 0.06 8 0.04 4 0.01 117 0.05 27 19 178
Chronic — — — — 1 0.00 23 0.01 4 9 37
Rabies
Human S S S S S S S S S S 3
Rubella S S S S S S S S S S 4
Rubella, congenital syndrome — — — — — — — — — — —
Salmonellosis (excluding paratyphoid fever and typhoid fever) ¶¶ 462 9.75 1,981 9.17 5,311 11.48 38,325 15.06 4,677 10,243 60,999
Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — —
Shiga toxin-producing Escherichia coli (STEC) 153 3.23 389 1.80 781 1.69 10,989 4.32 1,339 2,345 15,996
Shigellosis 104 2.19 560 2.59 2,774 6.00 8,638 3.39 1,733 2,524 16,333
Smallpox — — — — — — — — — — —
Spotted fever rickettsiosis
Total 40 0.87 19 0.09 139 0.30 3,641 1.44 156 1,549 5,544
Confirmed 10 0.22 1 0.00 3 0.01 73 0.03 9 28 124
Probable 30 0.65 18 0.09 136 0.29 3,568 1.41 147 1,521 5,420
Streptococcal toxic shock syndrome 1 0.04 17 0.15 49 0.15 247 0.15 15 42 371
Syphilis
Total, all stages *** 1,224 25.83 3,053 14.13 38,051 82.25 53,657 21.08 9,353 9,707 115,045
Congenital 32 75.93 27 9.60 518 81.76 649 22.89 29 51 1,306
Primary and secondary 418 8.82 971 4.50 11,490 24.84 16,974 6.67 2,600 2,610 35,063
Tetanus S S S S S S S S S S 23
Toxic shock syndrome (other than Streptococcal) — — 1 0.01 1 0.00 20 0.01 1 10 33
Trichinellosis S S S S S S S S S S 1
Tuberculosis 115 2.43 3,213 14.87 1,845 3.99 3,560 1.40 171 121 9,025
Tularemia 11 0.23 2 0.01 1 0.00 153 0.06 11 51 229
Typhoid fever 3 0.06 193 0.89 28 0.06 64 0.03 61 52 401
Vancomycin-intermediate Staphylococcus aureus — — — — 9 0.02 47 0.02 1 28 85
Vancomycin-resistant Staphylococcus aureus — — — — — — — — — — —
Varicella morbidity 83 2.31 422 2.28 526 1.38 4,526 2.18 398 2,246 8,201
Varicella mortality U U U U U U U U U U U
Vibriosis
Total 15 0.32 114 0.53 199 0.43 1,984 0.79 192 460 2,964
Confirmed 10 0.21 77 0.36 104 0.23 1,261 0.50 119 251 1,822
Probable 5 0.11 37 0.17 95 0.21 723 0.29 73 209 1,142
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus — — — — — — — — — — —
Ebola virus — — — — — — — — — — —
Guanarito virus — — — — — — — — — — —
Junin virus — — — — — — — — — — —
Lassa virus — — — — — — — — — — —
Lujo virus — — — — — — — — — — —
Machupo virus — — — — — — — — — — —
Marburg virus — — — — — — — — — — —
Sabia virus — — — — — — — — — — —
Yellow fever — — — — — — — — — — —
Zika virus
Zika virus disease, congenital ††† S S S S S S S S S S 2
Zika virus disease, non-congenital — — 3 0.01 — — 26 0.01 10 40 79
Zika virus infection, congenital ††† S S S S S S S S S S 8
Zika virus infection, non-congenital 1 0.02 10 0.05 41 0.09 104 0.04 14 75 245
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • U: Unavailable — The data are unavailable.
  • S: Suppressed
  • * Conditions with <25 cases reported in the year were not broken down by race.
  • † Race data were collected using current Office of Management and Budget (OMB) standards for race/ethnicity data and were mapped to bridged race categories.
  • § Reportable in <25 states.
  • ¶ Counts include confirmed and probable dengue cases.
  • ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm.
  • †† Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • §§ Prior to 2018, cases of paratyphoid fever were considered salmonellosis.
  • ¶¶ Prior to 2018, cases of paratyphoid fever were included as salmonellosis, but beginning in 2018 they are being published as paratyphoid fever.
  • *** Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); and unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations).
  • ††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01).
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  2. The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2018" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2017 by CSTE for national surveillance, that were implemented in January 2018, including updated surveillance case definitions for anthrax, shiga toxin-producing Escherichia coli, and syphilis. Perinatal hepatitis c virus infection became a new nationally notifiable condition in 2018. While Carbapenemase Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) was added to the list of nationally notifiable diseases in 2018, reporting jurisdictions could not submit data for this condition since Office of Management and Budget Paperwork Reduction Act approval was pending during 2018. Publication criteria for the finalized 2018 data are available at https://wonder.cdc.gov/nndss/documents/2018_NNDSS _Publication_Criteria_07122019_updated_09230219.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Annual tables for 2016 and later years are available on CDC WONDER.
  4. Annual summary reports from 1993-2015 are available as published in the MMWR.
  5. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).
  6. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a nationally notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Population estimates for incidence rates are July 1st, 2018 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2018, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2018), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 25, 2019 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2018 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on June 26, 2019 at https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal Hepatitis B infection (age restriction in numerator is ≤24 months, denominator is <24 months)
    • Perinatal Hepatitis C infection (age restriction in numerator is ≤36 months, denominator is <36 months)

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2018 (National Center for Health Statistics Natality 2018, as compiled from data provided by the Vital Statistics Cooperative Program). The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Congenital syphilis data are published in Syphilis Statistics in the Sexually Transmitted Diseases (STD) surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) and in the historical archives of the STD surveillance report (https://www.cdc.gov/std/stats/archive.htm). The STD surveillance report (https://www.cdc.gov/std/syphilis/stats.htm) updates congenital syphilis cases and rates over time.

  7. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
Suggested Citation: Acknowledgement:
  • CDC acknowledges the Local, State, and Territorial Health Departments that collected the data from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.